Key Takeaways
- Compounded semaglutide is a custom-prepared version of semaglutide made by a state-licensed compounding pharmacy in response to an individual prescription.
- It contains the same active pharmaceutical ingredient (semaglutide) found in Ozempic, Wegovy, and Rybelsus, but it is not FDA-approved and is not interchangeable with brand-name products.
- The compounded route exists because of the FDA's compounding pathway under sections 503A (traditional pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.
- Semaglutide was placed on the FDA Drug Shortage list in 2022 and removed in February 2025, which changed what 503A pharmacies could legally compound.
- After the shortage resolution, 503A pharmacies can still compound semaglutide for individual patients who need a clinically meaningful difference from the commercial product, such as a different dose or a documented allergy to an inactive ingredient.
- Common side effects (nausea, vomiting, diarrhea, constipation) and the boxed thyroid C-cell tumor warning still apply because the active molecule is the same.
Direct answer (40-60 words)
Compounded semaglutide is a custom-prepared version of the GLP-1 medication semaglutide, made by a state-licensed compounding pharmacy in response to an individual prescription. It contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved, not interchangeable with brand-name products, and subject to different oversight rules than commercial drugs.
Table of contents
- The 30-second answer
- What semaglutide is
- The legal basis for compounding: 503A and 503B
- How compounded semaglutide is actually prepared
- The drug shortage context (2022 to 2025)
- After the shortage resolution: what's allowed and what isn't
- How compounded semaglutide differs from the brand name
- Side effects and warnings (the same as brand)
- Quality questions to ask a compounding pharmacy
- Cost and access realities
- Who is and isn't a candidate
- FAQ
- Sources
- Footer disclaimers
What semaglutide is
Semaglutide is a 31-amino-acid synthetic peptide that mimics glucagon-like peptide-1 (GLP-1), a gut hormone the body releases after meals. Activating GLP-1 receptors does several things at once:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Stimulates insulin release from the pancreas (only when blood sugar is elevated)
- Suppresses glucagon, which prevents the liver from dumping glucose into the blood
- Slows gastric emptying, so meals stay in the stomach longer
- Acts on appetite centers in the brain to reduce hunger
These effects together produce both improved blood sugar control in type 2 diabetes and meaningful weight loss in obesity.
Novo Nordisk developed semaglutide and sells it under three brand names:
- Ozempic (subcutaneous injection, FDA-approved 2017 for type 2 diabetes)
- Wegovy (subcutaneous injection, FDA-approved 2021 for chronic weight management)
- Rybelsus (oral tablet, FDA-approved 2019 for type 2 diabetes)
When patients or providers say "compounded semaglutide," they almost always mean an injectable formulation similar in route of administration to Ozempic or Wegovy, but prepared by a compounding pharmacy rather than the original manufacturer.
The legal basis for compounding: 503A and 503B
Pharmacy compounding has been a recognized practice in the United States for over a century. The modern legal framework comes from sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which were updated by the Drug Quality and Security Act in 2013.
Section 503A covers traditional compounding pharmacies that prepare medications in response to an individual prescription. These pharmacies are state-licensed, meaning they're regulated primarily by state boards of pharmacy. They can compound a medication for a specific patient when:
- An FDA-approved version is on the FDA Drug Shortage list, or
- The patient needs a clinically meaningful difference from the commercial product (different strength, allergy to an excipient, alternative dosage form)
Section 503B covers outsourcing facilities that produce larger volumes of compounded medications, often without an individual prescription, for use in hospitals and clinics. These facilities register with and are inspected by the FDA, and they must comply with current Good Manufacturing Practice (cGMP) standards similar to those for FDA-approved drugs.
Both pathways are legal. Both have produced compounded semaglutide. The legal question that matters in 2026 is whether a particular compounding scenario fits one of the allowed exceptions.
How compounded semaglutide is actually prepared
A 503A or 503B pharmacy that compounds semaglutide typically follows this sequence:
- Source the active pharmaceutical ingredient (API). The pharmacy obtains semaglutide API from an FDA-registered bulk drug substance supplier. The supplier must be registered with the FDA under section 510 of the Act, and the API must come with a Certificate of Analysis (COA) showing identity, purity, and potency.
- Verify the COA. A licensed pharmacist reviews the COA and confirms the lot number, manufacture date, and test results match what was ordered.
- Prepare the diluent and excipients. The semaglutide is dissolved in a sterile aqueous solution, often with a buffer such as phosphate, a tonicity agent, and a preservative for multi-dose vials.
- Compound under sterile conditions. Sterile compounding follows USP Chapter 797 standards: ISO Class 5 primary engineering controls (a laminar flow hood or biological safety cabinet) inside an ISO Class 7 cleanroom, gowning protocols, and air sampling.
- Test or have tested. Sterility testing, endotoxin testing, and potency testing are performed on the finished product or on representative samples per USP <71>, <85>, and applicable monographs.
- Label and dispense. The vial or pen is labeled with the patient name, prescription information, beyond-use date (BUD), and storage instructions.
The beyond-use date is shorter than a brand drug's expiration date because compounded sterile preparations have less extensive stability data. Typical BUDs for compounded semaglutide are 28 to 90 days under refrigeration depending on the formulation and supporting stability evidence.
The drug shortage context (2022 to 2025)
Demand for semaglutide outpaced supply starting in 2022, and the FDA added semaglutide injection to the official Drug Shortage list in March 2022. Once a medication is on the shortage list, 503A pharmacies have an explicit legal pathway to compound it under section 503A(b)(1)(D) of the Act.
During the shortage:
- 503A pharmacies could compound semaglutide for individual patients with a valid prescription
- 503B outsourcing facilities could prepare and ship compounded semaglutide in larger volumes to clinics and providers
- Both pathways operated under their respective state and federal oversight rules
- A wide network of telehealth and clinic-based providers offered compounded semaglutide
In February 2025, the FDA declared the semaglutide shortage resolved. This restarted the clock on what compounding pharmacies could legally produce. After the resolution:
- 503A pharmacies can no longer compound a copy of an FDA-approved product simply because demand exists
- They can still compound for individual patients with documented clinical need (different dose, allergy to an excipient, etc.)
- 503B facilities lost the broad shortage pathway and now operate under tighter restrictions
- The FDA issued enforcement guidance with grace periods for pharmacies to wind down inventory
The legal landscape changed in early 2025, but the underlying compounding framework didn't disappear. Patients who legitimately need a customized formulation can still receive it through a 503A pharmacy.
After the shortage resolution: what's allowed and what isn't
The narrowed post-shortage rules look like this in practice:
Still allowed:
- A patient who needs a dose that doesn't exist in the commercial product (e.g., a half-strength starter dose for someone who can't tolerate the lowest commercial step)
- A patient with documented allergy or sensitivity to an inactive ingredient in the brand product
- A patient for whom a different formulation (different concentration, different preservative) is clinically necessary
- Compounding under a state-specific compounding regulation that authorizes it
No longer allowed under the broad shortage pathway:
- Identical copies of Ozempic or Wegovy without a clinically meaningful difference, on a non-prescription "online consultation" basis
- Mass-marketing of compounded semaglutide as a cheaper substitute for the brand
A reputable compounding pharmacy will document the clinical justification for each prescription and require an individualized provider relationship, not a one-click web form.
How compounded semaglutide differs from the brand name
The active pharmaceutical ingredient is the same molecule. The differences are in everything around the molecule.
| Brand semaglutide (Ozempic / Wegovy) | Compounded semaglutide | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval status | FDA-approved | Not FDA-approved |
| Manufacturing standard | cGMP, FDA-inspected facility | USP 797 / cGMP at a 503B; state pharmacy standards at a 503A |
| Inactive ingredients | Standardized formulation per FDA label | Vary by pharmacy |
| Dose forms available | Pre-filled multi-dose pens at fixed strengths | Vials or pens at flexible strengths |
| Stability data | Years of formal stability testing | Pharmacy-specific, often shorter BUDs |
| Lot tracking | Full pharmaceutical industry traceability | Pharmacy-level traceability |
| Insurance coverage | Often covered with prior authorization | Almost never covered |
| Cost (cash) | $900 to $1,300 per month | $200 to $600 per month |
Compounded semaglutide is not interchangeable with brand-name semaglutide for FDA-approval purposes. That phrasing matters legally and clinically. Saying "compounded semaglutide is the same as Ozempic" is not accurate. The molecule is the same. The product is not.
Side effects and warnings (the same as brand)
Because the active molecule is identical, the side effect profile and the boxed warning carry over from the brand label. The most common side effects, drawn from the STEP and SUSTAIN trial programs:
| Side effect | Semaglutide 2.4 mg (STEP-1) | Placebo |
|---|---|---|
| Nausea | 44.2% | 17.4% |
| Diarrhea | 31.5% | 15.9% |
| Vomiting | 24.8% | 6.6% |
| Constipation | 23.4% | 9.5% |
| Abdominal pain | 20.4% | 10.3% |
| Headache | 14.9% | 12.0% |
| Fatigue | 11.0% | 4.7% |
| Dizziness | 8.1% | 3.7% |
Source: Wilding et al., STEP-1 trial, N Engl J Med, 2021.
The boxed warning for thyroid C-cell tumors applies to all semaglutide, branded or compounded. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) cannot take semaglutide.
Other clinically significant safety considerations:
- Pancreatitis: rare but documented across the GLP-1 class
- Gallbladder disease: rate roughly double placebo, mostly during rapid weight loss
- Hypoglycemia: low risk with semaglutide alone, higher when combined with sulfonylureas or insulin
- Acute kidney injury: secondary to severe vomiting or diarrhea
- Diabetic retinopathy complications: more common in patients with pre-existing retinopathy
The compounded version carries one additional concern that doesn't apply to brand: ingredient quality. A poorly sourced API, a contaminated cleanroom, or an under-tested final product can produce safety problems unique to compounding. Choosing a pharmacy with strong quality systems matters.
Quality questions to ask a compounding pharmacy
A reputable 503A or 503B pharmacy will answer these questions in writing:
- Is the pharmacy state-licensed in good standing? Provide the license number and the state.
- If 503B, is the facility registered with the FDA? Provide the registration number.
- What is the source of the semaglutide API? Is the supplier FDA-registered under section 510?
- Can the pharmacy provide the Certificate of Analysis for the API lot in your prescription?
- What sterility, endotoxin, and potency testing is performed on the finished product?
- What is the beyond-use date and how was it determined?
- What inactive ingredients are in the formulation?
- Does the pharmacy carry general liability and product liability insurance?
- Has the pharmacy been the subject of FDA Form 483 observations or warning letters? When and what were the findings?
- What is the storage and shipping protocol? Is the cold chain maintained?
Pharmacies that decline to answer these questions, or that respond with marketing language instead of documentation, are worth avoiding. The best compounders treat these questions as routine and provide answers without friction.
Cost and access realities
Compounded semaglutide is almost always paid for in cash. Insurance plans cover FDA-approved medications, not compounded versions, with rare exceptions for clinically necessary customization.
Typical cash pricing in 2026:
- Compounded semaglutide injection (503A): $150 to $400 per month
- Compounded semaglutide injection (503B-distributed): $200 to $600 per month
- Brand Ozempic cash price: $900 to $1,000 per month
- Brand Wegovy cash price: $1,300 per month
The price gap is the main reason patients pursue compounded versions. For a patient who can afford brand and whose insurance covers it, brand is the cleaner choice. For a patient paying cash who cannot afford brand, a reputable compounded option is a reasonable alternative provided the clinical and quality questions above are answered satisfactorily.
The post-shortage legal narrowing in 2025 changed the access picture. Some online providers exited the market. Others restructured to focus on customized doses or formulations that fit within the post-shortage rules. Patients should expect more documentation, more questions about clinical history, and less "instant" access than was typical in 2023 and 2024.
Who is and isn't a candidate
Likely candidates for compounded semaglutide:
- Adults paying cash who cannot afford brand pricing and have no insurance coverage
- Patients with documented sensitivity to an inactive ingredient in the brand product
- Patients who need a dose between commercial steps and have a documented clinical reason
- Patients who have done the basic safety screening (no MTC family history, no pancreatitis history, no severe gastroparesis)
Not candidates:
- Patients with personal or family history of medullary thyroid carcinoma or MEN 2
- Patients with prior pancreatitis
- Pregnant or breastfeeding patients
- Patients with severe gastroparesis
- Patients with active eating disorders
- Patients under 18 (semaglutide is approved down to age 12 for obesity but compounded use in pediatric populations is rare and not recommended outside specialist care)
A licensed provider should make the candidacy call, not a website intake form alone.
FAQ
What is compounded semaglutide? Compounded semaglutide is a custom-prepared version of semaglutide made by a state-licensed compounding pharmacy in response to an individual prescription. It contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved.
Is compounded semaglutide the same as Ozempic? The active ingredient is the same. The products are not the same and are not interchangeable. Brand Ozempic is FDA-approved and manufactured under cGMP in an FDA-inspected facility. Compounded semaglutide is prepared per state pharmacy law and lacks FDA approval.
Is compounded semaglutide legal in 2026? Yes, when prepared for a specific patient with a clinically meaningful need that the brand product cannot meet. After the FDA declared the semaglutide shortage resolved in February 2025, the broad shortage-based compounding pathway narrowed. Patient-specific compounding still falls within section 503A.
Is compounded semaglutide as safe as Ozempic? The active ingredient has the same safety profile. Quality differences depend on the pharmacy. A high-quality compounder using FDA-registered API, USP 797 sterile technique, and validated testing produces a product whose risks closely resemble brand. A low-quality compounder can produce a product with elevated risks of contamination or potency variation.
How is compounded semaglutide dosed? Most patients start at 0.25 mg weekly, then titrate up over months to a maintenance dose between 1 mg and 2.4 mg. Compounded versions are sometimes prescribed in non-standard doses (0.125 mg, 0.5 mg) when clinically justified, which is one of the legitimate reasons to compound.
Why is compounded semaglutide cheaper than Ozempic? The compounding pharmacy doesn't carry the development, FDA approval, marketing, and patent costs that the brand manufacturer does. The active ingredient itself is a small fraction of the brand price. The savings reflect the simpler regulatory pathway and the absence of a patented commercial product premium.
Can I get compounded semaglutide through insurance? Almost never. Insurance plans cover FDA-approved drugs. Compounded semaglutide is paid for in cash in most cases. Some plans may reimburse compounded medications when an FDA-approved alternative is contraindicated, but this is rare and requires documentation.
Can I switch from compounded to brand semaglutide? Yes, with a prescription from your provider. Switching between formulations is straightforward as long as the dosing schedule is matched. Some patients use compounded during the lower titration steps and switch to brand once they reach a maintenance dose covered by insurance.
What are the side effects of compounded semaglutide? The same as brand: nausea, diarrhea, vomiting, constipation, headache, fatigue, and dizziness, mostly during titration. Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and the class-wide thyroid C-cell tumor boxed warning.
Is compounded semaglutide FDA-approved? No. Compounded medications are not FDA-approved. They are prepared per state pharmacy law (503A) or registered FDA outsourcing facility rules (503B), but neither pathway results in FDA approval of the finished product.
How long is compounded semaglutide good for? Beyond-use dates vary by pharmacy and formulation. Typical refrigerated BUDs range from 28 to 90 days. The pharmacy will print the BUD on the label. After that date, the medication should be discarded.
What's the difference between 503A and 503B compounded semaglutide? 503A pharmacies prepare medications for individual patients per prescription. 503B outsourcing facilities produce larger volumes for clinics and hospitals and follow stricter cGMP standards. After the shortage resolution, 503B's broad authority to compound semaglutide narrowed significantly.
Sources
- Wilding JPH, et al. STEP-1: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
- Marso SP, et al. SUSTAIN-6: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
- Davies M, et al. STEP-2: Semaglutide in adults with overweight or obesity and type 2 diabetes. Lancet. 2021;397:971-984.
- FDA. Drug Shortage list, semaglutide injection entry, original listing March 2022, resolution February 2025.
- FDA. Compounding and the FDA: Questions and Answers, current revision.
- United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding - Sterile Preparations.
- United States Pharmacopeia. USP General Chapter <71> Sterility Tests.
- United States Pharmacopeia. USP General Chapter <85> Bacterial Endotoxins Test.
- Drug Quality and Security Act, Public Law 113-54, signed November 27, 2013.
- Federal Food, Drug, and Cosmetic Act, sections 503A and 503B as amended.
- Ozempic Prescribing Information, Novo Nordisk, current revision.
- Wegovy Prescribing Information, Novo Nordisk, current revision.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.